Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study
NCT ID: NCT01694693
Last Updated: 2017-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2018-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA)
* To describe joint population of Orencia
* To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria
* To describe therapeutic strategies and use of health services
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg
NCT02600468
The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis
NCT03331393
Korean Post-marketing Surveillance for Orencia®
NCT01583244
Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL
NCT02600455
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
NCT05782335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Sampling Method: all physicians and sites taking in charge RA patients received an invitation mailing to participate to ORA
* Minimum Age: 18 years old at Orencia initiation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RA patients treated by Orencia
RA patients treated by Orencia according to usual practice from June 1st 2007
Orencia
No Intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orencia
No Intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with a rheumatoid arthritis according to ACR criteria
* Treated with Orencia according to usual practice conditions from June 1st 2007
* Agreeing to participate
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-364
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.